BioSpace News Archive

PDS Biotechnology Corporation announced upcoming poster presentations of clinical data from two Phase 2 clinical trials of PDS0101 at the 37th Annual Meeting for the Society for Immunotherapy of Cancer being held November 8-12, 2022 in Boston.

Iovance Biotherapeutics, Inc. announced the publication of abstracts reporting clinical data and a trial in progress for Iovance tumor-infiltrating lymphocyte cell therapies for the upcoming Society for Immunotherapy of Cancer Annual Meeting, November 8-12, 2022, in Boston, MA and virtually.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company announced a poster presentation highlighting the potential of the Company’s human neoantigen T-cell receptor platform to expand its TCR Library.

Humacyte, Inc. announced updated six-month results of the HAV in a baboon CABG model.

Apros Therapeutics, Inc. announced that they will present interim pharmacokinetic and pharmacodynamic Phase 1 clinical data for APR003 at the 2022 Society for Immunotherapy of Cancer Annual Meeting to be held November 8-12th in Boston, MA.

Nicox SA, an international ophthalmology company, announced future development and partnering plans for NCX 470, a novel nitric oxide -donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Sensorion announces that the US Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

TAAV Biomanufacturing Solutions, S.L., an independently operated wholly-owned subsidiary of Asklepios BioPharmaceutical, Inc., and a member of the Bayer worldwide group of companies, announced the appointment of Dolores Baksh, Ph.D. as Chief Executive Officer.

REGiMMUNE Limited announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease will be presented at the 2022 American Society of Hematology Annual Meeting in New Orleans, Louisiana on December 12, 2022.

HDT Bio Corp. announced it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response, a part of the U.S. Department of Health and Human Services.